...
首页> 外文期刊>Journal of human hypertension >Renal and cardiovascular risk predictive value of two different microalbuminuria screening methods in patients with hypertension with/without diabetes in Portugal
【24h】

Renal and cardiovascular risk predictive value of two different microalbuminuria screening methods in patients with hypertension with/without diabetes in Portugal

机译:葡萄牙有/无糖尿病的高血压患者两种不同微量白蛋白尿筛查方法的肾脏和心血管风险预测价值

获取原文
获取原文并翻译 | 示例
           

摘要

MicRoAlbuminuria sCreening survEy (RACE) was a multicentre, observational, cross-sectional study conducted in primary health-care settings of Portugal. Here, we present a post-hoc analysis from the RACE study, assessing the renal and cardiovascular (CV) risk predictive value of two different microalbuminuria (MA) screening methods, nephelometry with 24-h urine (MA-24 h) and Micral test with occasional urine (MicralA) in patients with hypertension (HTN) with/without type 2 diabetes mellitus (T2DM). Out of 3065 patients, 1173 (38.3%) were in the HTN group without T2DM (HTN) and 1892 (61.7%) in the HTN group with T2DM (HTN+T2DM). The overall prevalence of MA was 50.6% determined by MicralA and 22.1% with MA-24 h. Urinary albumin excretion data obtained by both techniques correlated significantly (r(s) = 0.586; P < 0.001). In all subjects, MicralA showed a sensitivity of 93%, specificity of 62% for detection of MA, with a positive predictive value of 41% and negative predictive value of 97%. With both methods, the presence of MA was independently associated with a higher risk (1.5- to 2.9-fold) of CV and renal organ damage in both HTN and HTN+T2DM groups. MicralA, due to its high sensitivity and negative predictive value, can be considered as a valid and reliable method for MA screening in patients with HTN with/without T2DM.
机译:微量白蛋白尿强化生存(RACE)是一项在葡萄牙的初级卫生保健机构进行的多中心,观察性横断面研究。在这里,我们提供了RACE研究的事后分析,评估了两种不同的微量白蛋白尿(MA)筛查方法,24小时尿液比浊法(MA-24 h)和Micral试验对肾脏和心血管(CV)风险的预测价值伴有或不伴有2型糖尿病(T2DM)的高血压(HTN)患者偶尔尿(MicralA)。在3065名患者中,无T2DM(HTN)的HTN组为1173名(38.3%),而有T2DM(HTN + T2DM)的HTN组为1892名(61.7%)。 MicralA测定的MA总体患病率为50.6%,MA-24 h的总体患病率为22.1%。通过两种技术获得的尿白蛋白排泄数据显着相关(r(s)= 0.586; P <0.001)。在所有受试者中,MicralA对MA的检测敏感性为93%,特异性为62%,阳性预测值为41%,阴性预测值为97%。通过这两种方法,在HTN和HTN + T2DM组中,MA的存在均与较高的CV和肾器官损害风险(1.5至2.9倍)相关。由于MicralA具有高灵敏度和阴性预测值,因此可以认为是对HTN伴/不伴T2DM的患者进行MA筛查的有效且可靠的方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号